Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma.
- Author:
Rong-cheng LI
1
;
Jin-ye YANG
;
Jian GONG
;
Yan-ping LI
;
Zhao-neng HUANG
;
Kong-xiong FANG
;
Zhi-yi XU
;
Chong-bai LIU
;
Kai ZHAO
;
Hui ZHUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Carcinoma, Hepatocellular; epidemiology; prevention & control; virology; Child; Child, Preschool; China; epidemiology; Cohort Studies; Cross-Sectional Studies; Hepatitis B; epidemiology; prevention & control; Hepatitis B Vaccines; immunology; Humans; Immunization Schedule; Infant; Liver Neoplasms; epidemiology; prevention & control; virology; Middle Aged; Prevalence; Vaccination; Vaccines, Synthetic; immunology
- From:Chinese Journal of Epidemiology 2004;25(5):385-387
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma.
METHODSBirth cohort study, cross-sectional seroepidemiological survey, and surveillance of hepatitis B (HBV) and hepatocellular carcinoma were used to evaluate the efficacy of hepatitis B vaccination.
RESULTSDuring the 14 years after hepatitis B vaccination, the HBsAg positive rates were found to be 0.7% - 2.9%, with an average of 1.5%, and the protective rates were 83.5% - 96.6%. Hepatitis B virus infection rates of children immunized with hepatitis B vaccine were 1.1% - 5.1%, with an average of 2.2% and the protective rates of 93.5% - 98.4%. 15 years after hepatitis B vaccination, the incidence of hepatitis B dropped from 3.27/10 000 to 0.17/10 000, a 94.8% decrease, in the group of 0 - 19 year-olds.
CONCLUSIONThe universal infant hepatitis B vaccination has proved to be effective in reducing the incidence rate of acute hepatitis B as well as the mortality of hepatocellular carcinoma.
